Pooled analysis on optimal management of MSI-high GEA

Evaluating pCR as a surrogate endpoint for OS in esophageal cancer

Pathological vs radiological response in neoadjuvant immunotherapy for HCC

Advancements in cellular therapy for GI cancers

Future directions for the ASPEN-06 trial in advanced gastric cancer

ASPEN-06: evaluating evorpacept plus TRP in HER2+ advanced gastric cancer

Multidisciplinary approach in treating immunotherapy-resistant GI cancers

The role of sintilimab with CRT and chemotherapy in ESCC

SCIENCE: chemoradiotherapy combined with sintilimab achieves high pCR rate

Pathological response as a predictor for relapse-free survival in early-stage HCC

Focusing on patient experience and future treatment developments in pancreatic cancer

Addressing geriatric vulnerabilities to improve pancreatic cancer outcomes

Understanding treatment approaches for older patients with metastatic pancreatic cancer

Key updates on ctDNA and immunotherapy in colorectal cancer

Early treatment response monitoring in gastrointestinal cancers with ctDNA

Evaluating tumor response with ctDNA

Examining neoadjuvant and adjuvant therapies in ESCC

The role of chemoradiotherapy in organ preservation for ESCC

Insights from JCOG trials: chemoradiotherapy as an alternative to surgery in ESCC

Analyzing two decades of trends in FDA approvals for GI cancer treatments

TCTP: a potential biomarker and therapeutic target in gastric cancer

Investigating TCTP as a biomarker for immunotherapy resistance in gastric cancer

Precision Promise: pamrevlumab with chemotherapy in pancreatic cancer

Advances in pamrevlumab for pancreatic cancer treatment

Importance of subgroup analyses to confirm treatment efficacy across diverse populations

T cell responses in responders vs. non-responders to oncolytic virotherapy in bladder cancer

Oncolytic virus therapy in early-stage bladder cancer w/ direct lesion contact via intravesical use

Oncolytic virus therapy + neoadjuvant chemo shows promise for bladder cancer response & preservation

SIERRA: Phase IIIb study of tremelimumab + durvalumab for 1L treatment of advanced unresectable HCC

5-year OS results of HIMALAYA: durvalumab + tremeliumab in unresectable hepatocellular carcinoma

Latest advances in biliary tract cancer: insights from the TOURMALINE and HERIZON-BTC-01 trials

Diagnostic accuracy of a blood based biomarker panel for CRC detection

RATIONALE-305: impact of tislelizumab + chemotherapy on patient-reported outcomes

ProvIDHe: baseline characteristics and molecular testing of pts with IDH1-mutated cholangiocarcinoma

Advancements and patient-centered care in GI oncology

LAPIS: pamrevlumab for locally advanced pancreatic cancer

Post-osimertinib landscape for NSCLC

GCC19CART, a novel CAR T-cell therapy, shows promise in colorectal cancer

ALASCCA: adjuvant aspirin in colorectal cancer

Evaluating the potential of aspirin in preventing recurrence in colorectal cancer

Blood-based tests could improve colorectal cancer screening rates

PREEMPT CRC: blood-based test for colorectal cancer screening

Exploring synergistic effects of IP chemotherapy in metastatic gastric cancer

ctDNA-guided immunotherapy in MSI-H stage III colon cancer

Impact of MTAP deletions on IO response and PRMT5 inhibition in GI cancers

Characterizing MTAP-deleted tumors in GI cancers using the Tempus database

Evaluating the side effects of 2L treatment for upper gastrointestinal cancer

Accessibility to diagnostic services for young patients with onset cancer

Addressing the holistic needs of young onset cancer patients

Exploring ABBV-400 in second-line colorectal cancer treatment

Future OrigAMI studies into amivantamab treatment for mCRC

Improvements in right-sided mCRC responses to amivantamab

DRAGON-01: IP paclitaxel + IV paclitaxel and S-1 to treat gastric cancer with peritoneal metastasis

Vaccines and cell therapy for hepatobiliary and pancreatic cancer

STARTER-NET: everolimus + lanreotide for gastroenteropancreatic neuroendocrine tumor

ctDNA as a biomarker for monitoring treatment response in pancreatic cancer

RMC-9805: Phase I results in patients with KRAS G12D pancreatic ductal adenocarcinoma

FOLFIRI-ramucirumab vs ramucirumab-paclitaxel in the 2L for upper gastrointestinal cancer

Optimizing the balance between efficacy & safety when administering T-DXd in gastric cancer

Real-world safety of trastuzumab deruxtecan in Japanese patients with gastric cancer